drugset / Trial / NCT02586168

The Effect of Gemcabene on Insulin Sensitivity in Nondiabetic Subjects

NCT02586168

Phase 2 Completed 53 enrolled NeuroBo Pharmaceuticals Inc.
RandomizedParallel-groupQuadruple-blindBasic science

Summary

The purpose of this study is to determine the effect of gemcabene on insulin sensitivity as defined by average glucose disposal rate.

Timeline

Start
2001-07
Primary completion
2001-10
Completion
2001-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Gemcabene Small molecule 900 mg

Indications

No indication recorded.